TheraRadar
← Back
Data updated: Mar 29, 2026

COVIS

RespiratoryInfectious DiseaseGastroenterology
Big Pharma

COVIS is a major pharmaceutical company focused on Respiratory, Infectious Disease, Gastroenterology. Key products include TUDORZA PRESSAIR.

1954
Since
13
Drugs
-
Trials
5
Approved (2yr)

Key Drugs

DUAKLIR PRESSAIR
aclidinium bromide
Respiratory
M3 1 indications · 2019
FERABRIGHT
ferumoxytol
Oncology
1 indications · 2025
TUDORZA PRESSAIR
aclidinium bromide
Respiratory
M1 1 indications · 2012

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

FERABRIGHT 2025-10-16
Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated
LANOXIN PEDIATRIC 2025-10-09
Labeling
RILUTEK 2025-09-11
Labeling
LANOXIN PEDIATRIC 2024-06-20
Labeling
LANOXIN 2024-04-29
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Respiratory 43%
3 drugs
Infectious Disease 14%
1 drugs
Gastroenterology 14%
1 drugs
Oncology 14%
1 drugs
Cardiovascular 14%
1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Pfizer big-pharma
Oncology, Infectious Disease, Gastroenterology
Novartis big-pharma
Oncology, Cardiovascular, Respiratory
GE HEALTHCARE specialty
Infectious Disease, Cardiovascular, Oncology, Respiratory
APOTHECON specialty
Infectious Disease, Cardiovascular, Gastroenterology, Respiratory
Merck big-pharma
Oncology, Infectious Disease, Cardiovascular